Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives Average Recommendation of “Hold” from Analysts

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has received a consensus rating of “Hold” from the seven brokerages that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and four have given a buy recommendation to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $4.25.

INO has been the subject of a number of research analyst reports. HC Wainwright lowered their price objective on shares of Inovio Pharmaceuticals from $3.00 to $2.50 and set a “neutral” rating for the company in a research report on Monday, June 1st. Wall Street Zen lowered shares of Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Sunday. Oppenheimer reissued an “outperform” rating on shares of Inovio Pharmaceuticals in a report on Friday, March 13th. Finally, Weiss Ratings raised shares of Inovio Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, June 16th.

Institutional Investors Weigh In On Inovio Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in INO. Boxer Capital Management LLC bought a new stake in Inovio Pharmaceuticals during the 3rd quarter worth approximately $5,382,000. Millennium Management LLC grew its holdings in Inovio Pharmaceuticals by 468.7% during the 3rd quarter. Millennium Management LLC now owns 1,972,518 shares of the biopharmaceutical company’s stock worth $4,616,000 after acquiring an additional 1,625,653 shares during the last quarter. Eversept Partners LP bought a new stake in Inovio Pharmaceuticals during the 1st quarter worth approximately $1,802,000. Vanguard Group Inc. grew its holdings in Inovio Pharmaceuticals by 35.0% during the 3rd quarter. Vanguard Group Inc. now owns 2,712,872 shares of the biopharmaceutical company’s stock worth $6,348,000 after acquiring an additional 703,727 shares during the last quarter. Finally, 683 Capital Management LLC bought a new stake in Inovio Pharmaceuticals during the 4th quarter worth approximately $433,000. 26.79% of the stock is owned by institutional investors.

Inovio Pharmaceuticals Price Performance

INO stock opened at $1.13 on Wednesday. The company has a 50 day simple moving average of $1.20 and a 200 day simple moving average of $1.53. The stock has a market cap of $92.97 million, a price-to-earnings ratio of -0.78 and a beta of 1.49. Inovio Pharmaceuticals has a 1 year low of $1.03 and a 1 year high of $2.98.

Inovio Pharmaceuticals (NASDAQ:INO) last released its quarterly earnings data on Wednesday, May 13th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.02. On average, equities research analysts anticipate that Inovio Pharmaceuticals will post -0.97 EPS for the current fiscal year.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.